HLC urged Congress to preserve incentives for continued biopharmaceutical innovation while pursuing solutions that improve affordability for beneficiaries. The letter raised concerns about proposals to expand Medicare drug price negotiation and impose additional pricing controls, while supporting efforts to strengthen Medicare Part D market stability, expand access to Low-Income Subsidy benefits, and improve uptake of existing affordability programs.
To Congress
HLC response to Senate Finance Committee Democrats’ RFI on Drug Pricing
- Topics: Access, Competition, Innovation
Related Letters & Comments
HLC drives policy change through strategic letters, comments, and reports that promote private-sector innovation. Focused on priorities like Medicare reform, telehealth, and health equity, HLC engages with lawmakers and agencies to shape a smarter, more responsive healthcare system.
To Congress
HLC response to Senate Finance Committee Democrats’ RFI on Drug Pricing
HLC urged Congress to preserve incentives for continued biopharmaceutical innovation while pursuing solutions that improve affordability for beneficiaries. The letter raised concerns about proposals to expand Medicare drug price negotiation and impo…
To The Administration
HLC letter to CMS in response to the Medicaid Community Engagement Requirement for Certain Individuals Interim Final Rule with Comment Period
The letter supports CMS' efforts to streamline verification of Medicaid community engagement requirements through automated, data-driven processes while expressing concern that manual verification of exemptions will increase administrative burden an…
To Congress
HLC group letter urging Congress to extend CISA 2015 in the upcoming continuing resolution
HLC joined a coalition of leading trade associations in calling on Congress to extend the Cybersecurity Information Sharing Act of 2015 (CISA 2015) in the upcoming continuing resolution. The letter underscores the importance of preserving voluntary …
